Contact Us
Drug Search Results
More Filters [+]

GSK-2256294

Alternative Names: gsk-2256294, gsk2256294, gsk 2256294
Latest Update: 2023-11-15
Latest Update Note: PubMed Publication

Product Description

GSK-2256294 is a potent, reversible, tight binding inhibitor of isolated recombinant human sEH (soluble epoxide hydrolase) (IC50 = 27 pM; t1/2 = 121 min) and displays potent inhibition against the rat (IC50 = 61 pM) and murine (IC50 = 189 pM) orthologs of sEH. (Sourced from: https://drugs.ncats.io/substance/L33EX3XR0T)

Mechanisms of Action: EPHX Inhibitor

Novel Mechanism: Yes

Modality: Small Molecule

Route of Administration: Oral

FDA Designation: None *

Approval Status: Not Approved

Approved Countries: None

Approved Indications: None

Known Adverse Events: None

Company: GlaxoSmithKline
Company Location: BRENTFORD MIDDLESEX X0 TW8 9GS
Company CEO: Emma Walmsley
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for GSK-2256294

Countries in Clinic:

Active Clinical Trial Count:

Highest Development Phases

Phase 2: Intracranial Aneurysm|Vasospasm, Intracranial|Subarachnoid Hemorrhage|Ischemic Stroke|Brain Infarction|Cerebral Hemorrhage|Glucose Metabolism Disorders|Obesity|Prediabetes

Phase 1: Chronic Obstructive Pulmonary Disease|Hypoxia

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success
5R01DK117875

P2

Completed

Prediabetes|Glucose Metabolism Disorders|Obesity

2021-11-18

SUSHI

P2

Completed

Ischemic Stroke|Subarachnoid Hemorrhage|Brain Infarction|Cerebral Hemorrhage|Intracranial Aneurysm|Vasospasm, Intracranial

2019-04-03

NCT02262689

P1

Completed

Hypoxia|Chronic Obstructive Pulmonary Disease

2015-04-24

NCT02006537

P1

Completed

Chronic Obstructive Pulmonary Disease

2014-05-27

Recent News Events

Date

Type

Title

11/15/2023

PubMed

 Soluble epoxide hydrolase inhibitors for smoking-associated inflammatory lung diseases and chronic obstructive pulmonary disease: a meta-analytical systematic review of preclinical and clinical studies.

06/01/2022

PubMed

 A Double-Blind, Randomized, Placebo-Controlled Trial of Soluble Epoxide Hydrolase Inhibition in Patients with Aneurysmal Subarachnoid Hemorrhage.

02/01/2022

PubMed

 The soluble epoxide hydrolase inhibitor GSK2256294 decreases the proportion of adipose pro-inflammatory T cells.

Did PRYZM just deliver the data you were looking for?
Did you try our Excel download too?

Now that you’ve used PRYZM, we hope you’re able to see for yourself that it was designed and developed by people who actually use this data for a living. By applying next-generation technology for aggregating and curating this info across multiple key sources PRYZM delivering the latest information at your fingertips just the way you need it and with industry leading speed and cost effectiveness.

Our subscribers enjoy unlimited searches and receive this data on their own secure instance so they can overlay any additional internal/proprietary data on top of the search results and blend that data with real-time industry intel from PRYZM. Discover how you can continue to uncover the competitive landscape and drive strategy.

Suggestions